Form D · Biotechnology
Mesentech Inc.
Vancouver, A1 · CIK 0001922136
Offering snapshot reported Apr 14, 2022 · SEC filing
- Reported sold
- $3.89M Offering amount: $7M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 31, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2022 | Initial | $3,891,947 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-441826
The Board approved a total worldwide financing of USD7,000,000. The Company may sell securities to new investors within 90 days from the date of First Sale but there is no indication whether securities will in fact be sold subsequent to the First Sale.
Equity: Preferred Shares
Source: Form D, filed Apr 14, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Dvorak | Director |
| David Hyman | Executive |
| Jay Mohr | Director |
| Jonathan Polak | Director, Executive, Promoter |
| Samuel Wu | Director |
| Barbara Yanni | Director |
| Robert Norman Young | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2222 Health Sciences Mall
Vancouver, A1, V6T 1Z3
Vancouver, A1, V6T 1Z3